Prana Biotechnology Limited (ADR)  

(Public, NASDAQ:PRAN)   Watch this stock  
Find more results for PRAN
+0.02 (1.79%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.13 - 1.16
52 week 1.07 - 2.94
Open 1.13
Vol / Avg. 151,175.00/497,327.00
Mkt cap 57.34M
P/E     -
Div/yield     -
EPS -0.11
Shares 488.94M
Beta 0.49
Inst. own 0%

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -1353.10% -3664.09%
Operating margin -4884.77% -3442.31%
EBITD margin - -3436.16%
Return on average assets -6.14% -45.40%
Return on average equity -6.74% -51.60%
Employees 12 -
CDP Score - -


L 2 369 Royal Pde, Parkville
+61-3-93494906 (Phone)
+61-3-93480377 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Prana Biotechnology Limited (Prana) is an Australia-based development stage medical biotechnology Company. The Company is engaged in commercializing research into Alzheimer's disease, Huntington disease and other major age-related degenerative disorders. The Company's lead drug candidate, PBT2 is being developed for the treatment of Alzheimer�s and Huntington's diseases. Prana Biotechnology is developing therapies to treat neurodegenerative disease. Prana Biotechnology also has advanced a drug candidate for Parkinson�s disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. The Company's activities are predominantly within Australia and cover research into Alzheimer's disease and other major age-related degenerative disorders.

Officers and directors

Geoffrey Paul Kempler Executive Chairman of the Board, Chief Executive Officer
Bio & Compensation  - Reuters
Kathryn Andrews Chief Financial Officer
Bio & Compensation  - Reuters
Dianne Angus Chief Operating Officer
Bio & Compensation  - Reuters
Phillip Hains Company Secretary
Bio & Compensation  - Reuters
Ira Shoulson Director
Bio & Compensation  - Reuters
Lawrence Gozlan Non-Executive Independent Director
Bio & Compensation  - Reuters
Peter Ashley Marks Non-Executive Independent Director
Bio & Compensation  - Reuters
Brian Derek Meltzer Non-Executive Independent Director
Bio & Compensation  - Reuters
George William Mihaly Non-Executive Independent Director
Bio & Compensation  - Reuters